In the United States, approximately 100,000 people develop hyperparathyroidism each year. Approximately, 85% of cases are due to parathyroid adenomas, whereas 10 to 20% are due to four-gland hyperplasia, of which many of these cases are associated with renal disease. 1 The following is a report, approved by the University of North Carolina Institutional Review Board, of a patient treated for presumed tertiary hyperparathyroidism, whose operative procedure and pathology report highlight important learning points in the management of patients with hyperparathyroidism.
Case ReportA 45-year-old African-American male with a history of hypertension, diabetes mellitus, morbid obesity, and endstage renal disease on dialysis for 4 years with refractory hypercalcemia (Ca: 10.6-11.8 mg/dL over the prior 12 months) despite 3 days per week hemodialysis presented with tertiary hyperparathyroidism refractory to cinacalcet to the otolaryngology clinic in August 2014 for planned parathyroidectomy for the presumed four-gland disease. He had undergone a left below-knee amputation in January 2014 for progressive peripheral vascular disease and had a history of a CVA (cerebrovascular accident) 2 years prior. He had a calcium level at the time of evaluation in clinic of 9.8 mg/ dL, which corrected to 10.6 mg/dL (albumin level 3.0), and a parathyroid hormone (PTH) level of 1,422 pg/mL. In clinic, ultrasonography was performed and demonstrated two distinct hypoechoic round, approximately 1 cm in size, left central compartment masses presumed to be the inferior
AbstractHyperparathyroidism is a common disorder affecting more than hundreds of thousands of people annually. While most commonly secondary to an adenoma, it may also arise from four-gland hyperplasia or malignancy. In the case of primary hyperparathyroidism, the number of glands involved may be unknown prior to surgery. In contrast, the metabolic disorder associated with renal failure induced hyperparathyroidism ensures a hyperplasia picture. Despite the uniform hyperplasia seen in tertiary disease and the preoperative expectation for four-gland exploration, our case demonstrates the continued need for a surgeon's vigilance during dissection to identify all glands and appropriately use intraoperative parathyroid hormone (PTH) testing. In addition, while intraoperative PTH assessment is an effective method for confirming adequacy of treatment for hyperparathyroidism, only surgical pathology can confirm malignancy, which should be considered with PTH levels > 1,000. The case also underscores the importance of comprehensive surgery management and mindful interpretation of intraoperative PTH levels in the management of hyperparathyroidism. Standard surgical technique includes complete exploration of the central compartment, and thyroid lobectomy when the aforementioned exploration fails to reveal the necessary parathyroid tissue, especially with a persistently elevated PTH. Without a standardized progressive compartment exploration and judicious use of intraoperative hormone testin...